MeiraGTx Holdings (FRA:328) Research & Development: €110.74 Mil (TTM As of Mar. 2026)


FRA:328 MeiraGTx Holdings PLC FRA:328
51 GF Score
Price €10.30
GF Value €21.06
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is MeiraGTx Holdings Research & Development?

MeiraGTx Holdings FRA:328 +4.04% 51 Research & Development is €110.74 Mil as of Mar. 2026. GuruFocus rates FRA:328 with a GF Score™ of 51/100 and a GF Value™ of €21.06 (Possible Value Trap). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. MeiraGTx Holdings's Research & Development for the three months ended in Mar. 2026 was €27.67 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €110.74 Mil.

MeiraGTx Holdings  (FRA:328) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

MeiraGTx Holdings Research & Development Related Terms

MeiraGTx Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for MeiraGTx Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MeiraGTx Holdings Research & Development Chart

MeiraGTx Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 59.02 80.92 95.17 114.11 110.70

MeiraGTx Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.32 29.04 27.72 26.31 27.67
FRA:328
51GF Score
MeiraGTx Holdings PLC FRA:328
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MeiraGTx Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €110.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €110.74 Mil mean?
MeiraGTx Holdings (FRA:328) has a Research & Development of €110.74 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on MeiraGTx Holdings and its competitors.
Is MeiraGTx Holdings' Research & Development too high?
MeiraGTx Holdings' current Research & Development is €110.74 Mil. Overall, MeiraGTx Holdings has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MeiraGTx Holdings' Research & Development compare to DRTS and LXRX?
MeiraGTx Holdings' Research & Development of €110.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on MeiraGTx Holdings and its competitors. MeiraGTx Holdings's current Research & Development is €110.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeiraGTx Holdings stock overvalued right now?
Based on GuruFocus' analysis, MeiraGTx Holdings (FRA:328) is currently considered Possible Value Trap. The stock's GF Value™ is €21.06, compared to a current price of €10.30 — trading 51.1% below its estimated fair value. The current Research & Development is €110.74 Mil. MeiraGTx Holdings' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For MeiraGTx Holdings (FRA:328), the current Research & Development is €110.74 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MeiraGTx Holdings (FRA:328) Overvalued in 2026?

Based on GuruFocus' analysis, MeiraGTx Holdings stock appears to be undervalued. The current stock price of €10.30 is trading 51.1% below its estimated GF Value™ of €21.06. GuruFocus considers MeiraGTx Holdings to be Possible Value Trap.

Key valuation signals for FRA:328:

  • Research & Development: €110.74 Mil
  • GF Value™: €21.06 vs. price of €10.30 (51.1% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the FRA:328 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MeiraGTx Holdings Business Description

Other Exchanges MGTX:USA328:Germany
Address 655 Third Avenue, Suite 1115, New York, NY, USA, 10017
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
51GF Score

Get the complete analysis for FRA:328

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.30
Price
€21.06
GF Value